Stock TGTX TG THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
16.3 USD -3.49% Intraday chart for TG Therapeutics, Inc. -2.45% -4.57%
May. 01 Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts MT
May. 01 Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts
Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024
TG Therapeutics: Q1 Earnings Snapshot
Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
North American Morning Briefing : Investors Brace -2-
TG Therapeutics Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Sector Update: Health Care
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TGTX Stock
  4. News TG Therapeutics, Inc.
  5. Other languages